CN112521496B - 特异性结合SARS-CoV-2 Spike RBD的单克隆抗体及其应用 - Google Patents
特异性结合SARS-CoV-2 Spike RBD的单克隆抗体及其应用 Download PDFInfo
- Publication number
- CN112521496B CN112521496B CN202110126719.XA CN202110126719A CN112521496B CN 112521496 B CN112521496 B CN 112521496B CN 202110126719 A CN202110126719 A CN 202110126719A CN 112521496 B CN112521496 B CN 112521496B
- Authority
- CN
- China
- Prior art keywords
- cov
- sars
- spike rbd
- rbd
- spike
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 title claims abstract description 150
- 229920001184 polypeptide Polymers 0.000 claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 9
- 239000013604 expression vector Substances 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 5
- 210000004408 hybridoma Anatomy 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 102100031673 Corneodesmosin Human genes 0.000 description 5
- 101710139375 Corneodesmosin Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 2
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 2
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 2
- UOXPLPBMEPLZBW-WDSOQIARSA-N Trp-Val-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 UOXPLPBMEPLZBW-WDSOQIARSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 108010081404 acein-2 Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 108010093581 aspartyl-proline Proteins 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 108010003137 tyrosyltyrosine Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- CEHZCZCQHUNAJF-AVGNSLFASA-N (2s)-1-[2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(O)=O)CCC1 CEHZCZCQHUNAJF-AVGNSLFASA-N 0.000 description 1
- TTXMOJWKNRJWQJ-FXQIFTODSA-N Ala-Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N TTXMOJWKNRJWQJ-FXQIFTODSA-N 0.000 description 1
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 1
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 1
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 1
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- DYXOFPBJBAHWFY-JBDRJPRFSA-N Ala-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N DYXOFPBJBAHWFY-JBDRJPRFSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 1
- VNFSAYFQLXPHPY-CIQUZCHMSA-N Ala-Thr-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNFSAYFQLXPHPY-CIQUZCHMSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- OTOXOKCIIQLMFH-KZVJFYERSA-N Arg-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N OTOXOKCIIQLMFH-KZVJFYERSA-N 0.000 description 1
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- XSPKAHFVDKRGRL-DCAQKATOSA-N Arg-Pro-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XSPKAHFVDKRGRL-DCAQKATOSA-N 0.000 description 1
- 108010051330 Arg-Pro-Gly-Pro Proteins 0.000 description 1
- WCZXPVPHUMYLMS-VEVYYDQMSA-N Arg-Thr-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O WCZXPVPHUMYLMS-VEVYYDQMSA-N 0.000 description 1
- QNJIRRVTOXNGMH-GUBZILKMSA-N Asn-Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(N)=O QNJIRRVTOXNGMH-GUBZILKMSA-N 0.000 description 1
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 1
- VLDRQOHCMKCXLY-SRVKXCTJSA-N Asn-Ser-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O VLDRQOHCMKCXLY-SRVKXCTJSA-N 0.000 description 1
- KRXIWXCXOARFNT-ZLUOBGJFSA-N Asp-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O KRXIWXCXOARFNT-ZLUOBGJFSA-N 0.000 description 1
- TVVYVAUGRHNTGT-UGYAYLCHSA-N Asp-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O TVVYVAUGRHNTGT-UGYAYLCHSA-N 0.000 description 1
- PGUYEUCYVNZGGV-QWRGUYRKSA-N Asp-Gly-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PGUYEUCYVNZGGV-QWRGUYRKSA-N 0.000 description 1
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 1
- RVMXMLSYBTXCAV-VEVYYDQMSA-N Asp-Pro-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMXMLSYBTXCAV-VEVYYDQMSA-N 0.000 description 1
- SXLCDCZHNCLFGZ-BPUTZDHNSA-N Asp-Pro-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O SXLCDCZHNCLFGZ-BPUTZDHNSA-N 0.000 description 1
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 1
- BRRPVTUFESPTCP-ACZMJKKPSA-N Asp-Ser-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O BRRPVTUFESPTCP-ACZMJKKPSA-N 0.000 description 1
- XYPJXLLXNSAWHZ-SRVKXCTJSA-N Asp-Ser-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XYPJXLLXNSAWHZ-SRVKXCTJSA-N 0.000 description 1
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 1
- QYTKAVBFRUGYAU-ACZMJKKPSA-N Gln-Asp-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QYTKAVBFRUGYAU-ACZMJKKPSA-N 0.000 description 1
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 1
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 1
- XSBGUANSZDGULP-IUCAKERBSA-N Gln-Gly-Lys Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O XSBGUANSZDGULP-IUCAKERBSA-N 0.000 description 1
- KQOPMGBHNQBCEL-HVTMNAMFSA-N Gln-His-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KQOPMGBHNQBCEL-HVTMNAMFSA-N 0.000 description 1
- GXMBDEGTXHQBAO-NKIYYHGXSA-N Gln-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)N)N)O GXMBDEGTXHQBAO-NKIYYHGXSA-N 0.000 description 1
- WLRYGVYQFXRJDA-DCAQKATOSA-N Gln-Pro-Pro Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 WLRYGVYQFXRJDA-DCAQKATOSA-N 0.000 description 1
- SYZZMPFLOLSMHL-XHNCKOQMSA-N Gln-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N)C(=O)O SYZZMPFLOLSMHL-XHNCKOQMSA-N 0.000 description 1
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 1
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
- OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 description 1
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 1
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 1
- RFTVTKBHDXCEEX-WDSKDSINSA-N Glu-Ser-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RFTVTKBHDXCEEX-WDSKDSINSA-N 0.000 description 1
- DMYACXMQUABZIQ-NRPADANISA-N Glu-Ser-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O DMYACXMQUABZIQ-NRPADANISA-N 0.000 description 1
- JVZLZVJTIXVIHK-SXNHZJKMSA-N Glu-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N JVZLZVJTIXVIHK-SXNHZJKMSA-N 0.000 description 1
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 1
- MFVQGXGQRIXBPK-WDSKDSINSA-N Gly-Ala-Glu Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFVQGXGQRIXBPK-WDSKDSINSA-N 0.000 description 1
- OCQUNKSFDYDXBG-QXEWZRGKSA-N Gly-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OCQUNKSFDYDXBG-QXEWZRGKSA-N 0.000 description 1
- XBWMTPAIUQIWKA-BYULHYEWSA-N Gly-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN XBWMTPAIUQIWKA-BYULHYEWSA-N 0.000 description 1
- DTRUBYPMMVPQPD-YUMQZZPRSA-N Gly-Gln-Arg Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DTRUBYPMMVPQPD-YUMQZZPRSA-N 0.000 description 1
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- HAXARWKYFIIHKD-ZKWXMUAHSA-N Gly-Ile-Ser Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HAXARWKYFIIHKD-ZKWXMUAHSA-N 0.000 description 1
- LPHQAFLNEHWKFF-QXEWZRGKSA-N Gly-Met-Ile Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LPHQAFLNEHWKFF-QXEWZRGKSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- HRGGKHFHRSFSDE-CIUDSAMLSA-N His-Asn-Ser Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N HRGGKHFHRSFSDE-CIUDSAMLSA-N 0.000 description 1
- TVMNTHXFRSXZGR-IHRRRGAJSA-N His-Lys-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O TVMNTHXFRSXZGR-IHRRRGAJSA-N 0.000 description 1
- YEKYGQZUBCRNGH-DCAQKATOSA-N His-Pro-Ser Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)N)C(=O)N[C@@H](CO)C(=O)O YEKYGQZUBCRNGH-DCAQKATOSA-N 0.000 description 1
- FLXCRBXJRJSDHX-AVGNSLFASA-N His-Pro-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O FLXCRBXJRJSDHX-AVGNSLFASA-N 0.000 description 1
- FONIDUOGWNWEAX-XIRDDKMYSA-N His-Trp-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O FONIDUOGWNWEAX-XIRDDKMYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- FBGXMKUWQFPHFB-JBDRJPRFSA-N Ile-Ser-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N FBGXMKUWQFPHFB-JBDRJPRFSA-N 0.000 description 1
- UYODHPPSCXBNCS-XUXIUFHCSA-N Ile-Val-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(C)C UYODHPPSCXBNCS-XUXIUFHCSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 1
- OXKYZSRZKBTVEY-ZPFDUUQYSA-N Leu-Asn-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OXKYZSRZKBTVEY-ZPFDUUQYSA-N 0.000 description 1
- KAFOIVJDVSZUMD-DCAQKATOSA-N Leu-Gln-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-DCAQKATOSA-N 0.000 description 1
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 1
- LOLUPZNNADDTAA-AVGNSLFASA-N Leu-Gln-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LOLUPZNNADDTAA-AVGNSLFASA-N 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- FIYMBBHGYNQFOP-IUCAKERBSA-N Leu-Gly-Gln Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N FIYMBBHGYNQFOP-IUCAKERBSA-N 0.000 description 1
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
- FAELBUXXFQLUAX-AJNGGQMLSA-N Leu-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C FAELBUXXFQLUAX-AJNGGQMLSA-N 0.000 description 1
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 1
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 1
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 1
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
- DIBZLYZXTSVGLN-CIUDSAMLSA-N Lys-Ser-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O DIBZLYZXTSVGLN-CIUDSAMLSA-N 0.000 description 1
- RMKJOQSYLQQRFN-KKUMJFAQSA-N Lys-Tyr-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O RMKJOQSYLQQRFN-KKUMJFAQSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- DTICLBJHRYSJLH-GUBZILKMSA-N Met-Ala-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O DTICLBJHRYSJLH-GUBZILKMSA-N 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- ABHVWYPPHDYFNY-WDSOQIARSA-N Met-His-Trp Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CN=CN1 ABHVWYPPHDYFNY-WDSOQIARSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108010066427 N-valyltryptophan Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- KIEPQOIQHFKQLK-PCBIJLKTSA-N Phe-Asn-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KIEPQOIQHFKQLK-PCBIJLKTSA-N 0.000 description 1
- FRPVPGRXUKFEQE-YDHLFZDLSA-N Phe-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O FRPVPGRXUKFEQE-YDHLFZDLSA-N 0.000 description 1
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 1
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 1
- GNRMAQSIROFNMI-IXOXFDKPSA-N Phe-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GNRMAQSIROFNMI-IXOXFDKPSA-N 0.000 description 1
- CVAUVSOFHJKCHN-BZSNNMDCSA-N Phe-Tyr-Cys Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(O)=O)C1=CC=CC=C1 CVAUVSOFHJKCHN-BZSNNMDCSA-N 0.000 description 1
- BQMFWUKNOCJDNV-HJWJTTGWSA-N Phe-Val-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQMFWUKNOCJDNV-HJWJTTGWSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- VCYJKOLZYPYGJV-AVGNSLFASA-N Pro-Arg-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VCYJKOLZYPYGJV-AVGNSLFASA-N 0.000 description 1
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 1
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 1
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 1
- SMFQZMGHCODUPQ-ULQDDVLXSA-N Pro-Lys-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SMFQZMGHCODUPQ-ULQDDVLXSA-N 0.000 description 1
- XSXABUHLKPUVLX-JYJNAYRXSA-N Pro-Ser-Trp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O XSXABUHLKPUVLX-JYJNAYRXSA-N 0.000 description 1
- PGSWNLRYYONGPE-JYJNAYRXSA-N Pro-Val-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PGSWNLRYYONGPE-JYJNAYRXSA-N 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- QFBNNYNWKYKVJO-DCAQKATOSA-N Ser-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N QFBNNYNWKYKVJO-DCAQKATOSA-N 0.000 description 1
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 description 1
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 1
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- FGBLCMLXHRPVOF-IHRRRGAJSA-N Ser-Tyr-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FGBLCMLXHRPVOF-IHRRRGAJSA-N 0.000 description 1
- YXGCIEUDOHILKR-IHRRRGAJSA-N Ser-Tyr-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)N YXGCIEUDOHILKR-IHRRRGAJSA-N 0.000 description 1
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 1
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 description 1
- CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 description 1
- LIXBDERDAGNVAV-XKBZYTNZSA-N Thr-Gln-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O LIXBDERDAGNVAV-XKBZYTNZSA-N 0.000 description 1
- CRZNCABIJLRFKZ-IUKAMOBKSA-N Thr-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N CRZNCABIJLRFKZ-IUKAMOBKSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 1
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 1
- LECUEEHKUFYOOV-ZJDVBMNYSA-N Thr-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)[C@@H](C)O LECUEEHKUFYOOV-ZJDVBMNYSA-N 0.000 description 1
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 1
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 1
- FEZASNVQLJQBHW-CABZTGNLSA-N Trp-Gly-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O)=CNC2=C1 FEZASNVQLJQBHW-CABZTGNLSA-N 0.000 description 1
- RCMHSGRBJCMFLR-BPUTZDHNSA-N Trp-Met-Asn Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(O)=O)=CNC2=C1 RCMHSGRBJCMFLR-BPUTZDHNSA-N 0.000 description 1
- CDRYEAWHKJSGAF-BPNCWPANSA-N Tyr-Ala-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O CDRYEAWHKJSGAF-BPNCWPANSA-N 0.000 description 1
- TZXFLDNBYYGLKA-BZSNNMDCSA-N Tyr-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 TZXFLDNBYYGLKA-BZSNNMDCSA-N 0.000 description 1
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 1
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 1
- DZKFGCNKEVMXFA-JUKXBJQTSA-N Tyr-Ile-His Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O DZKFGCNKEVMXFA-JUKXBJQTSA-N 0.000 description 1
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 1
- RZAGEHHVNYESNR-RNXOBYDBSA-N Tyr-Trp-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RZAGEHHVNYESNR-RNXOBYDBSA-N 0.000 description 1
- LABUITCFCAABSV-BPNCWPANSA-N Val-Ala-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LABUITCFCAABSV-BPNCWPANSA-N 0.000 description 1
- LABUITCFCAABSV-UHFFFAOYSA-N Val-Ala-Tyr Natural products CC(C)C(N)C(=O)NC(C)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LABUITCFCAABSV-UHFFFAOYSA-N 0.000 description 1
- CVUDMNSZAIZFAE-UHFFFAOYSA-N Val-Arg-Pro Natural products NC(N)=NCCCC(NC(=O)C(N)C(C)C)C(=O)N1CCCC1C(O)=O CVUDMNSZAIZFAE-UHFFFAOYSA-N 0.000 description 1
- JLFKWDAZBRYCGX-ZKWXMUAHSA-N Val-Asn-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N JLFKWDAZBRYCGX-ZKWXMUAHSA-N 0.000 description 1
- HURRXSNHCCSJHA-AUTRQRHGSA-N Val-Gln-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N HURRXSNHCCSJHA-AUTRQRHGSA-N 0.000 description 1
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 description 1
- CPGJELLYDQEDRK-NAKRPEOUSA-N Val-Ile-Ala Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(O)=O CPGJELLYDQEDRK-NAKRPEOUSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 1
- XBJKAZATRJBDCU-GUBZILKMSA-N Val-Pro-Ala Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O XBJKAZATRJBDCU-GUBZILKMSA-N 0.000 description 1
- JQTYTBPCSOAZHI-FXQIFTODSA-N Val-Ser-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N JQTYTBPCSOAZHI-FXQIFTODSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- UJMCYJKPDFQLHX-XGEHTFHBSA-N Val-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N)O UJMCYJKPDFQLHX-XGEHTFHBSA-N 0.000 description 1
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 1
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010084758 arginyl-tyrosyl-aspartic acid Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Abstract
本发明公开一种特异性结合SARS‑CoV‑2 Spike RBD的单克隆抗体,为SARS‑CoV‑2 Spike RBD/2E10;本发明还公开了包含ARS‑CoV‑2 Spike RBD/2E10和SARS‑CoV‑2 Spike RBD/6E2的单克隆抗体、包含SARS‑CoV‑2 Spike RBD/2E10和HRP‑SARS‑CoV‑2 Spike RBD/6E2的单克隆抗体;同时还公开了一种表达载体,以及所述单克隆抗体的应用。所述单克隆抗体,可结合并识别SARS‑CoV‑2 Spike RBD的多肽链,用于SARS‑CoV‑2 Spike RBD的检测及药物制备。
Description
技术领域
本发明属于生物医学技术领域,具体涉及特异性结合SARS-CoV-2 Spike RBD的单克隆抗体及其应用。
背景技术
SARS-CoV-2 Spike protein (S蛋白) 是冠状病毒最重要的表面蛋白,与病毒的传染能力及发病机制等密切相关。S蛋白是一类很大的三聚体跨膜蛋白,可以被分成两个功能单位:S1和S2蛋白亚基。S1包含受体结合区域(receptor binding domain,RBD)部分,负责识别和结合细胞受体。
研究发现冠状病毒人传人的特性是由衣壳表面棘突蛋白(S蛋白)与宿主细胞表面受体的相互作用实现的。因此,病毒S蛋白与受体表面的相互作用可以定量的评价病毒的传播能力。石正丽等报道SARS-CoV-2 Spike RBD与人体细胞表面的ACE2受体结合进入细胞。ACE2是人类的一个重要的细胞表面受体,广泛分布于人的心脏、肾脏、睾丸、胃肠道、大脑和肺内。
S蛋白也是宿主中和抗体的重要作用位点,针对与SARS-CoV-2 Spike RBD抗体的研究不仅适用于新冠病毒的临床检测,还可应用于开发抗新冠病毒的药物。然而,目前尚未有SARS-CoV-2 Spike RBD浓度检测方法应用于相关疾病的临床诊断。
发明内容
针对现有技术的缺陷,本发明提供一种特异性结合SARS-CoV-2 Spike RBD的单克隆抗体及其在抗SARS-CoV-2 Spike RBD药物制备及检测中的应用。
特异性结合SARS-CoV-2 Spike RBD的单克隆抗体,所述单克隆抗体为SARS-CoV-2Spike RBD/2E10,所述SARS-CoV-2 Spike RBD/2E10识别并结合SARS-CoV-2 Spike RBD的多肽链;所述SARS-CoV-2 Spike RBD/2E10的轻链可变区的氨基酸序列如SEQ.ID.NO.1所示,所述SARS-CoV-2 Spike RBD/2E10的重链可变区的氨基酸序列如SEQ.ID.NO.2所示。
编码所述单克隆抗体的基因,编码SARS-CoV-2 Spike RBD/2E10的轻链可变区的基因序列如SEQ.ID.NO.5所示;编码SARS-CoV-2 Spike RBD/2E10的重链可变区的基因序列如SEQ.ID.NO.6所示。
特异性结合SARS-CoV-2 Spike RBD的单克隆抗体,包含两种抗体,分别为SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2,所述SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2识别并结合SARS-CoV-2 Spike RBD的多肽链;
所述SARS-CoV-2 Spike RBD/6E2的轻链可变区的氨基酸序列如SEQ.ID.NO.3所示,所述SARS-CoV-2 Spike RBD/6E2的重链可变区的氨基酸序列如SEQ.ID.NO.4所示;
所述SARS-CoV-2 Spike RBD/2E10采用上述单克隆抗体SARS-CoV-2 Spike RBD/2E10。
编码所述特异性结合SARS-CoV-2 Spike RBD的单克隆抗体的基因,所述单克隆抗体包含两种抗体,分别为SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2;编码SARS-CoV-2 Spike RBD/2E10的轻链可变区的基因序列如SEQ.ID.NO.5所示;编码SARS-CoV-2 Spike RBD/2E10的重链可变区的基因序列如SEQ.ID.NO.6所示;编码SARS-CoV-2Spike RBD/6E2的轻链可变区的基因序列如SEQ.ID.NO.7所示;编码SARS-CoV-2 SpikeRBD/6E2的重链可变区的基因序列如SEQ.ID.NO.8所示。
特异性结合SARS-CoV-2 Spike RBD的单克隆抗体,包含两种抗体,分别为SARS-CoV-2 Spike RBD/2E10和HRP-SARS-CoV-2 Spike RBD/6E2,所述SARS-CoV-2 Spike RBD/2E10和HRP-SARS-CoV-2 Spike RBD/6E2识别并结合SARS-CoV-2 Spike RBD的多肽链;所述HRP-SARS-CoV-2 Spike RBD/6E2为HRP标记的SARS-CoV-2 Spike RBD/6E2;
所述SARS-CoV-2 Spike RBD/6E2的轻链可变区的氨基酸序列如SEQ.ID.NO.3所示,所述SARS-CoV-2 Spike RBD/6E2的重链可变区的氨基酸序列如SEQ.ID.NO.4所示;
所述 SARS-CoV-2 Spike RBD/2E10采用上述单克隆抗体SARS-CoV-2 Spike RBD/2E10。
编码所述特异性结合SARS-CoV-2 Spike RBD的单克隆抗体的基因,所述单克隆抗体包含两种抗体,分别为SARS-CoV-2 Spike RBD/2E10和HRP-SARS-CoV-2 Spike RBD/6E2,所述HRP-SARS-CoV-2 Spike RBD/6E2为HRP标记的SARS-CoV-2 Spike RBD/6E2;编码SARS-CoV-2 Spike RBD/2E10的轻链可变区的基因序列如SEQ.ID.NO.5所示;编码SARS-CoV-2Spike RBD/2E10的重链可变区的基因序列如SEQ.ID.NO.6所示;编码SARS-CoV-2 SpikeRBD/6E2的轻链可变区的基因序列如SEQ.ID.NO.7所示;编码SARS-CoV-2 Spike RBD/6E2的重链可变区的基因序列如SEQ.ID.NO.8所示。
一种表达载体,所述表达载体含有上述单克隆抗体中的基因序列SEQ.ID.NO.5、SEQ.ID.NO.6 、SEQ.ID.NO.7 和SEQ.ID.NO.8。
所述单克隆抗体用于抗SARS-CoV-2的药物的制备的应用;优选地,所述单克隆抗体包含两种抗体,分别为SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2,所述SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2识别并结合SARS-CoV-2 SpikeRBD的多肽链。
所述单克隆抗体用于SARS-CoV-2 Spike RBD检测的应用;优选地,所述单克隆抗体包含两种抗体,分别为SARS-CoV-2 Spike RBD/2E10和HRP-SARS-CoV-2 Spike RBD/6E2,所述SARS-CoV-2 Spike RBD/2E10和HRP-SARS-CoV-2 Spike RBD/6E2识别并结合SARS-CoV-2 Spike RBD的多肽链;所述HRP-SARS-CoV-2 Spike RBD/6E2为HRP标记的SARS-CoV-2Spike RBD/6E2。
更优选地,所述单克隆抗体用于SARS-CoV-2 Spike RBD检测的应用,所述应用具体为SARS-CoV-2 Spike RBD诊断试剂的制备。
本发明的优点:
本发明提供的单克隆抗体,可结合并识别SARS-CoV-2 Spike RBD的多肽链,用于SARS-CoV-2 Spike RBD的检测及药物制备,能够为SARS-CoV-2 Spike RBD的检测应用于临床诊断奠定基础。
附图说明
图1 利用SDS-PAGE检测SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2单抗的纯化结果。
图2 利用western-blot法检测SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 SpikeRBD/6E2单抗与SARS-CoV-2 Spike RBD的反应结果。
图3 利用SARS-CoV-2 Spike RBD/2E10和HRP- SARS-CoV-2 Spike RBD/6E2双抗体夹心法,检测SARS-CoV-2 Spike RBD标准品得到标准曲线。
具体实施方式
本发明采用重组表达的SARS-CoV-2 Spike RBD免疫BALB/c小鼠,制备了一组分泌小鼠SARS-CoV-2 Spike RBD单克隆抗体的杂交瘤细胞株,从中筛选出能稳定分泌高亲和力单克隆抗体SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2的杂交瘤细胞株,制备腹水并纯化出单克隆抗体;提取所述杂交瘤细胞株的RNA,反转录成cDNA,PCR扩增获得所述单抗的轻链可变区序列和重链可变区序列,通过比对确认该序列的唯一性;使用HRP标记SARS-CoV-2 Spike RBD/6E2单抗;利用SARS-CoV-2 Spike RBD/2E10和HRP-SARS-CoV-2Spike RBD/6E2双抗体夹心法检测SARS-CoV-2 Spike RBD。
具体实施步骤如下:
1. SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2单抗的制备和鉴定
1.1动物免疫
利用SARS-CoV-2 Spike RBD重组蛋白免疫8周龄BALB/c小鼠(购自空军军医大学实验动物中心),初次免疫:取50μg/只SARS-CoV-2 Spike RBD-His重组蛋白与150μL/只弗氏完全佐剂等体积混合,重分乳化后,背部皮下多点注射,4周后取小鼠血清进行抗体效价检测,选择抗体效价高的个体继续背部皮下多点注射进行加强免疫,然后每2周免疫一次,共进行4次免疫,第4次免疫时不加佐剂腹腔注射抗原SARS-CoV-2 Spike RBD-His重组蛋白50μg /只,3天后取脾细胞,备用。
1.2 杂交瘤细胞制备
采用PEG1500为融合剂,将免疫小鼠脾细胞悬液与小鼠骨髓瘤细胞SP2/0按细胞数量3:1的比例进行融合。融合细胞接种至含滋养细胞(6周龄BALB/c鼠胸腺细胞)96孔细胞培养板中,采用含1%HAT、20%FBS的1640培养基进行筛选培养获得42株杂交瘤细胞。当杂交瘤克隆细胞生长至1/3-1/2底面积时,收集培养上清,SARS-CoV-2 Spike RBD-His重组蛋白以25ng/孔包被于酶标板中,Elisa法检测培养上清中的抗体,经筛选获得2株可稳定分泌抗SARS-CoV-2 Spike RBD抗体的杂交瘤细胞株2E10和6E2,所分泌的抗体分别命名为SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2。
1.3 SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2单抗纯化
BALB/c小鼠腹腔注射灭菌石蜡油500μL/只,小鼠平均分为两组,两周后腹腔分别注射2E10和6E2杂交瘤细胞1×106细胞/只,一周后抽取腹水。3000r/min离心5min,去除血细胞,上清液经15000r/min离心30min, 上清液经0.22μm过滤后,向其中缓慢加入3倍体积的醋酸盐缓冲液;向上述溶液中缓慢加入正辛酸(1mL腹水加入25 μL),室温搅拌10min, 4℃、10000rpm离心20min后弃沉淀,测上清液体积,过滤;加入上清液1/10体积的10XPBS,调节pH至7.4,按1:1比例向其中缓慢加入饱和硫酸铵,调节pH至7;4℃静置沉淀过夜;次日,将上述液体全部倒入离心管中,离心后沉淀用PBS重悬,透析过夜,SDS-PAGE检测纯化抗体,如图1所示。
由图1可知,经正辛酸-饱和硫酸铵沉淀法纯化获得较纯的 SARS-CoV-2 SpikeRBD/2E10和SARS-CoV-2 Spike RBD/6E2单克隆抗体。
1.4 SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2单抗鉴定
以SARS-CoV-2 Spike RBD为抗原,western-blot方法检测SARS-CoV-2 SpikeRBD/2E10和SARS-CoV-2 Spike RBD/6E2单抗与重组SARS-CoV-2 Spike RBD的结合,SARS-CoV-2 Spike RBD(0.5μg)蛋白煮沸后上样,26mA,转膜2.5h后,用5%脱脂牛奶封闭2h;TBST洗膜后按1:1000比例加入2E10和6E2单克隆抗体作为一抗,4℃ 孵育过夜;次日按1:2000比例加入山羊抗小鼠IgG-HRP抗体作为二抗,室温孵育1h,TBST洗膜后,用凝胶成像系统曝光成像,结果如图2所示。由图2可知,所述单抗SARS-CoV-2 Spike RBD/2E10、SARS-CoV-2Spike RBD/6E2可以与SARS-CoV-2 Spike RBD抗原结合。
1.5 抗体轻链和重链可变区的克隆
培养SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2杂交瘤细胞,收集细胞,利用Trizol法提取细胞RNA,利用抗体可变区保守引物进行PCR扩增,扩增条件:94℃ 5min;94℃ 90s, 50℃ 90s, 72℃ 2min (35 cycles); 72℃ 10min。扩增产物连接pMD18-T载体,转化大肠杆菌感受态JM109,筛选阳性克隆,提取质粒,进行测序鉴定,测序结果进行Ig BLAST比对分析,得到单克隆抗体6E2和2E10的轻链、重链可变区编码基因序列,计算出SARS-CoV-2 Spike RBD/2E10轻链可变区氨基酸序列如SEQ.ID.NO.1所示,重链可变区氨基酸序列如SEQ.ID.NO.2所示,SARS-CoV-2 Spike RBD/6E2轻链可变区氨基酸序列如SEQ.ID.NO.3所示,重链可变区氨基酸序列如SEQ.ID.NO.4所示。
2 HRP标记SARS-CoV-2 Spike RBD/6E2单抗
取10mg纯化的SARS-CoV-2 Spike RBD/6E2抗体,置于碳酸盐缓冲液(pH=9.4)中透析。称取辣根过氧化物酶HRP 20mg(抗体:HRP=1:2)及高碘酸钠128mg,用超纯水溶解后配制预混酶溶液,室温避光放置30 min;将上述酶溶液加至抗体中,4℃透析过夜。取出透析过夜的HRP标记的抗体,分别加入320 μl硼氢化钠及等体积饱和硫酸铵溶液,4℃避光静置2 h;5000rpm离心30 min,弃上清,PBS溶解沉淀,溶液呈砖红色,置于PBS溶液中透析过夜,即获得HRP标记的6E2检测抗体。
3 SARS-CoV-2 Spike RBD/2E10和HRP- SARS-CoV-2 Spike RBD/6E2双抗体夹心法检测SARS-CoV-2 Spike RBD
用碳酸盐缓冲液稀释捕获抗体SARS-CoV-2 Spike RBD/2E10至2.5 μg/mL,进行酶标板包被,100 μL/孔,4℃过夜;2% BSA溶液37℃封闭1h, 200 μL/孔;用封闭液对SARS-CoV-2 Spike RBD从100 ng/ mL开始倍比稀释(100ng/ mL,50 ng/ mL,25ng/ mL,12.5 ng/mL,6.25 ng/ mL,3.125 ng/ mL,0),将稀释好的抗原依次加入到包被好SARS-CoV-2 SpikeRBD/2E10的酶标板中,100 μL/孔,37℃孵育1h;加入用封闭液稀释(1:1000)的HRP- SARS-CoV-2 Spike RBD/6E2, 100 μL/孔,37℃孵育1h;加入显色底物(TMB)100 μL /孔,避光孵育5 min;加终止液50 μL/孔,采用酶标仪检测每孔液体在波长为450 nm处的吸光度值,以吸光度为纵坐标y,稀释浓度(ng/ mL)为横坐标x,拟合的标准曲线如图3所示,检测条件见表1:
表1
由图3可知,单克隆抗体SARS-CoV-2 Spike RBD/2E10 和HRP- SARS-CoV-2 SpikeRBD/6E2组合进行双抗夹心实验检测SARS-CoV-2 Spike RBD具有高线性度,可用于SARS-CoV-2 Spike RBD的定量检测。
SEQUENCE LISTING
<110> 中国人民解放军空军军医大学
<120> 特异性结合SARS-CoV-2 Spike RBD的单克隆抗体及其应用
<130> 20201216
<160> 8
<170> PatentIn version 3.3
<210> 1
<211> 110
<212> PRT
<213> 人工合成
<400> 1
Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln
1 5 10 15
Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly
20 25 30
Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys
35 40 45
Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg
50 55 60
Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro
65 70 75 80
Val Glu Ala Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Asp Asn Glu
85 90 95
Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
<210> 2
<211> 120
<212> PRT
<213> 人工合成
<400> 2
Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Pro
1 5 10 15
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
20 25 30
Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe
50 55 60
Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80
Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Asp Gly Tyr Tyr Trp Tyr Phe Asp Val Trp Gly Ala Gly
100 105 110
Thr Thr Val Thr Val Ser Ser Ala
115 120
<210> 3
<211> 128
<212> PRT
<213> 人工合成
<400> 3
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15
Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala
20 25 30
Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Tyr Arg Ala Ser Lys Ser
35 40 45
Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Asn Gln Gln Lys Pro
50 55 60
Gly Gln Pro Pro Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser
65 70 75 80
Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
85 90 95
Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys
100 105 110
Gln His Ile Arg Glu Leu Thr Arg Ser Glu Gly Gly Pro Ser Trp Lys
115 120 125
<210> 4
<211> 185
<212> PRT
<213> 人工合成
<400> 4
Met Ala Val Val Thr Gly Val Asn Ser Glu Val Gln Val Gln Gln Ser
1 5 10 15
Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Thr
20 25 30
Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp Val Lys Gln
35 40 45
Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Arg Ile Asp Pro Thr Asn
50 55 60
Asp Asp Ile Lys Tyr Asp Pro Lys Phe Gln Gly Lys Ala Ser Ile Thr
65 70 75 80
Ala Asp Thr Ser Ser Asn Val Ala Tyr Leu Gln Leu Ser Ser Leu Thr
85 90 95
Ser Glu Asp Thr Ala Val Phe Tyr Cys Ala Ser Arg Tyr Asp Tyr Val
100 105 110
Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
115 120 125
Ala Lys Thr Thr Pro Pro Pro Val Tyr Pro Leu Ala Pro Gly Ser Leu
130 135 140
Gly Ile Ser Arg Gly Ser Pro Gly Thr Glu Leu Glu Phe Val Ile Met
145 150 155 160
Val Ile Ala Val Ser Cys Val Lys Leu Leu Ser Ala His Asn Ser Thr
165 170 175
Gln His Thr Ser Arg Lys His Lys Val
180 185
<210> 5
<211> 330
<212> DNA
<213> 人工合成
<400> 5
attgtgttga cccaatctcc agcttctttg gcggtgtctc tagggcagag ggccaccata 60
tcctgcagag ccagtgaaag tgttgatagt tatggcaata gttttatgca ctggtaccag 120
cagaaaccag gacagccacc caaactcctc atctatcttg catccaacct agaatctggg 180
gtccctgcca ggttcagtgg cagtgggtct aggacagact tcaccctcac cattgatcct 240
gtggaggctg ctgatgctgc aacctattac tgtcagcaag ataatgagga tccgtggacg 300
ttcggtggag gcaccaagct ggaaatcaaa 330
<210> 6
<211> 360
<212> DNA
<213> 人工合成
<400> 6
caggtccaac tgcagcagcc tggggctgag ctggtgaggc ctggaccttc agtgaagctg 60
tcctgcaagg cttctggcta ttccttcacc agctactgga tgaactgggt gaagcagagg 120
cctggacaag gccttgagtg gattggcatg attcatcctt ccgatagtga aactaggtta 180
aatcagaagt tcaaggacaa ggccacattg actgtagaca aatcctccag cacagcctac 240
atgcaactca gcagcccgac atctgaggac tctgcggtct attactgtgc aagatcggac 300
ggctactatt ggtacttcga tgtctggggc gcagggacca cggtcaccgt ctcctcagcc 360
<210> 7
<211> 387
<212> DNA
<213> 人工合成
<400> 7
atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60
gacattgtgc tgacacagtc tcctgcttcc ttagctgtat ctctggggca gagggccacc 120
atctcataca gggccagcaa aagtgtcagt acatctggct atagttatat gcactggaac 180
caacagaaac caggacagcc acccagactc ctcatctatc ttgtatccaa cctagaatct 240
ggggtccctg ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat 300
cctgtggagg aggaggatgc tgcaacctat tactgtcagc acattaggga gcttacacgt 360
tcggaggggg gaccaagctg gaaataa 387
<210> 8
<211> 558
<212> DNA
<213> 人工合成
<400> 8
atggcagtgg ttacaggggt caattcagag gttcaggtac agcaatctgg ggcagagctt 60
gtgaagccag gggcctcagt caagttgtcc tgcacagctt ctggcttcaa cattaaagac 120
acctatattc actgggtgaa acagaggcct gaacagggcc tggagtggat tggaaggatt 180
gatcctacga atgatgatat taaatatgac ccgaagtttc agggcaaggc ctctataaca 240
gcagacacat cctccaatgt agcctacctg cagctcagca gcctgacatc tgaggacact 300
gccgtctttt actgtgctag tcgctatgat tacgtctatg ctatggacta ctggggtcaa 360
ggaacgtcag tcaccgtctc ctctgccaaa acgacacccc cacctgttta tcccctggcc 420
cctggaagct tgggaatctc tagaggatcc ccgggtaccg agctcgaatt cgtaatcatg 480
gtcatagctg tttcctgtgt gaaattgtta tccgctcaca attccacaca acatacgagc 540
cggaagcata aagtgtaa 558
Claims (6)
1.特异性结合SARS-CoV-2 Spike RBD的单克隆抗体,其特征在于:包含两种抗体,分别为SARS-CoV-2 Spike RBD/2E10和SARS-CoV-2 Spike RBD/6E2,所述SARS-CoV-2 SpikeRBD/2E10和SARS-CoV-2 Spike RBD/6E2识别并结合SARS-CoV-2 Spike RBD的多肽链;
所述SARS-CoV-2 Spike RBD/6E2的轻链可变区的氨基酸序列如SEQ.ID.NO.3所示,所述SARS-CoV-2 Spike RBD/6E2的重链可变区的氨基酸序列如SEQ.ID.NO.4所示;
所述SARS-CoV-2 Spike RBD/2E10的轻链可变区的氨基酸序列如SEQ.ID.NO.1所示,所述SARS-CoV-2 Spike RBD/2E10的重链可变区的氨基酸序列如SEQ.ID.NO.2所示。
2.编码权利要求1所述特异性结合SARS-CoV-2 Spike RBD的单克隆抗体的基因,其特征在于:编码SARS-CoV-2 Spike RBD/2E10的轻链可变区的基因序列如SEQ.ID.NO.5所示;编码SARS-CoV-2 Spike RBD/2E10的重链可变区的基因序列如SEQ.ID.NO.6所示;编码SARS-CoV-2 Spike RBD/6E2的轻链可变区的基因序列如SEQ.ID.NO.7所示;编码SARS-CoV-2 Spike RBD/6E2的重链可变区的基因序列如SEQ.ID.NO.8所示。
3.特异性结合SARS-CoV-2 Spike RBD的单克隆抗体,其特征在于:包含两种抗体,分别为SARS-CoV-2 Spike RBD/2E10和HRP-SARS-CoV-2 Spike RBD/6E2,所述SARS-CoV-2Spike RBD/2E10和HRP-SARS-CoV-2 Spike RBD/6E2识别并结合SARS-CoV-2 Spike RBD的多肽链;所述HRP-SARS-CoV-2 Spike RBD/6E2为HRP标记的SARS-CoV-2 Spike RBD/6E2;
所述SARS-CoV-2 Spike RBD/6E2的轻链可变区的氨基酸序列如SEQ.ID.NO.3所示,所述SARS-CoV-2 Spike RBD/6E2的重链可变区的氨基酸序列如SEQ.ID.NO.4所示;
所述SARS-CoV-2 Spike RBD/2E10的轻链可变区的氨基酸序列如SEQ.ID.NO.1所示,所述SARS-CoV-2 Spike RBD/2E10的重链可变区的氨基酸序列如SEQ.ID.NO.2所示。
4.编码权利要求3所述单克隆抗体的基因,其特征在于:编码SARS-CoV-2 Spike RBD/2E10的轻链可变区的基因序列如SEQ.ID.NO.5所示;编码SARS-CoV-2 Spike RBD/2E10的重链可变区的基因序列如SEQ.ID.NO.6所示;编码SARS-CoV-2 Spike RBD/6E2的轻链可变区的基因序列如SEQ.ID.NO.7所示;编码SARS-CoV-2 Spike RBD/6E2的重链可变区的基因序列如SEQ.ID.NO.8所示。
5.一种表达载体,其特征在于:所述表达载体含有权利要求2所述单克隆抗体中的基因序列SEQ.ID.NO.5、SEQ.ID.NO.6 、SEQ.ID.NO.7 和SEQ.ID.NO.8。
6.权利要求3所述单克隆抗体用于制备SARS-CoV-2 Spike RBD诊断试剂的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110126719.XA CN112521496B (zh) | 2021-01-29 | 2021-01-29 | 特异性结合SARS-CoV-2 Spike RBD的单克隆抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110126719.XA CN112521496B (zh) | 2021-01-29 | 2021-01-29 | 特异性结合SARS-CoV-2 Spike RBD的单克隆抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112521496A CN112521496A (zh) | 2021-03-19 |
CN112521496B true CN112521496B (zh) | 2022-09-06 |
Family
ID=74975482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110126719.XA Expired - Fee Related CN112521496B (zh) | 2021-01-29 | 2021-01-29 | 特异性结合SARS-CoV-2 Spike RBD的单克隆抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112521496B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202103404PA (en) | 2020-04-02 | 2021-04-29 | Regeneron Pharma | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
WO2022068847A1 (zh) * | 2020-09-29 | 2022-04-07 | 山东博安生物技术股份有限公司 | 一种治疗或预防新型冠状病毒SARS-CoV-2引起的疾病的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111732655A (zh) * | 2020-07-01 | 2020-10-02 | 中国人民解放军军事科学院军事医学研究院 | 靶向RBD的高中和活性抗SARS-CoV-2全人源单克隆抗体及应用 |
CN111978395A (zh) * | 2020-07-20 | 2020-11-24 | 四川大学 | 抗新型冠状病毒rbd结构域抗原的单克隆抗体 |
CN112010965A (zh) * | 2020-05-15 | 2020-12-01 | 潍坊医学院 | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 |
CN112250763A (zh) * | 2020-12-21 | 2021-01-22 | 三优生物医药(上海)有限公司 | 靶向SARS-CoV-2冠状病毒的抗体及其诊断和检测用途 |
-
2021
- 2021-01-29 CN CN202110126719.XA patent/CN112521496B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112010965A (zh) * | 2020-05-15 | 2020-12-01 | 潍坊医学院 | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 |
CN111732655A (zh) * | 2020-07-01 | 2020-10-02 | 中国人民解放军军事科学院军事医学研究院 | 靶向RBD的高中和活性抗SARS-CoV-2全人源单克隆抗体及应用 |
CN111978395A (zh) * | 2020-07-20 | 2020-11-24 | 四川大学 | 抗新型冠状病毒rbd结构域抗原的单克隆抗体 |
CN112250763A (zh) * | 2020-12-21 | 2021-01-22 | 三优生物医药(上海)有限公司 | 靶向SARS-CoV-2冠状病毒的抗体及其诊断和检测用途 |
Also Published As
Publication number | Publication date |
---|---|
CN112521496A (zh) | 2021-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112094343B (zh) | 与SARS-CoV-2 RBD结合的羊驼源纳米抗体 | |
CN109438576B (zh) | 一种抗人cd47单克隆抗体的制备及其应用 | |
CN110066336B (zh) | 抗cd47单克隆抗体、片段及其医药用途 | |
CN112521496B (zh) | 特异性结合SARS-CoV-2 Spike RBD的单克隆抗体及其应用 | |
CN110526968B (zh) | 一种金黄色葡萄球菌肠毒素b纳米抗体b7、应用及试剂盒 | |
CN113150151B (zh) | 一种C5aR抗体及其制备方法和应用 | |
CN110526966B (zh) | 一种金黄色葡萄球菌肠毒素b纳米抗体b6、应用及试剂盒 | |
CN110563839A (zh) | 一种金黄色葡萄球菌肠毒素b纳米抗体b1、应用及试剂盒 | |
US20210002699A1 (en) | Tim-3 nanobody, a preparation method thereof, and use thereof | |
CN111533805A (zh) | 一种抗癌胚抗原的高亲和力纳米抗体及其应用 | |
CN110577594B (zh) | 一种金黄色葡萄球菌肠毒素a纳米抗体a21、应用及试剂盒 | |
CN108484758B (zh) | 抗埃博拉病毒vp40蛋白单克隆抗体a2g7及其应用 | |
CN106866820B (zh) | 一种用于捕获肿瘤细胞的抗人角蛋白18的单克隆抗体及其应用 | |
CN110684102B (zh) | 一种sftsv检测试剂盒 | |
He et al. | High affinity monoclonal antibody targeting Siglec-15 for cancer immunotherapy | |
CN108997500B (zh) | 一种抗人pd-l1抗体及其应用 | |
CN112521497B (zh) | 肌红蛋白单克隆抗体的制备和应用 | |
CN107266576B (zh) | 一种1-氨基环丙烷-1-羧酸氧化酶的单克隆抗体及其应用 | |
CN109021103B (zh) | 抗人血管内皮生长因子的抗体及其制备方法和应用 | |
CN113527474A (zh) | 一种抗新冠病毒n蛋白的单克隆抗体及其应用 | |
CN115232206B (zh) | 抗CD2v蛋白单克隆抗体及其应用 | |
WO2015186721A1 (ja) | 抗体またはその可変領域を含む抗体断片、抗原ポリペプチド、およびその利用 | |
CN113583119A (zh) | 抗金黄色葡萄球菌的纳米抗体Nb56、应用及试剂盒 | |
Sotoudeh et al. | Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4) | |
CN112094350B (zh) | 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220906 |